DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Brigimadlin

Generic Name: Brigimadlin

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₂₅Cl_₂FN_₄O_₃

CAS Number: 2095116-40-6

Unique Ingredient Identifier: 9A934ZAN94

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Phase 2

Recruiting

Posted: 2024/10/01

Sponsor:Boehringer Ingelheim

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Phase 3

Withdrawn

Posted: 2024/04/17

Sponsor:Boehringer Ingelheim

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 3

Active, not recruiting

Posted: 2023/09/28

Sponsor:Boehringer Ingelheim

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Phase 1

Completed

Posted: 2022/11/14

Sponsor:Boehringer Ingelheim

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Phase 2

Active, not recruiting

Posted: 2022/08/23

Sponsor:Boehringer Ingelheim

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Brigimadlin Shows Promise in Treating Dedifferentiated Liposarcoma

7 months ago

Brigimadlin (BI 907828) is an oral MDM2-p53 antagonist showing potential in treating dedifferentiated liposarcoma (DDLPS) by restoring normal p53 activity.

Boehringer Ingelheim Plans 25 New Treatments by 2030, Bolstered by Oncology and Metabolic Disease Programs

a year ago

Boehringer Ingelheim aims to launch 25 new treatments by 2030, focusing on oncology, mental health, cardiovascular, renal, and metabolic diseases.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy